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Background: Adolescents living with perinatally-acquired HIV (APHIV) face challenges
including HIV serostatus disclosure. We assessed their 24-month outcomes in relation
to the disclosure of their own HIV serostatus.
Methods: Nested within the International epidemiologic Database to Evaluate AIDS
pediatric West African prospective cohort (IeDEA pWADA), the COHADO cohort included
antiretroviral (ART)-treated APHIV aged 10–19 years, enrolled in HIV care before the
age of 10 years, in Abidjan (Côte d’Ivoire) and Lomé (Togo) in 2015. We measured the
HIV serostatus disclosure at baseline and after 24 months and analyzed its association
with a favorable combined 24-month outcome using logistic regression. The 24-month
combined clinical immuno-virological outcome was defined as unfavorable when either
death, loss to follow-up, progression to WHO-AIDS stage, a decrease of CD4 count
>10% compared to baseline, or a detectable viral load (VL > 50 copies/mL) occurred
at 24 months.
Results: Overall, 209 APHIV were included (51.6% = Abidjan, 54.5% = females). At
inclusion, the median CD4 cell count was 521/mm3 [IQR (281–757)]; 29.6% had a VL
measurement, of whom, 3.2% were virologically suppressed. APHIV were younger in
Lomé {median age: 12 years [interquartile range (IQR): 11–15]} compared to Abidjan [14
years (IQR: 12–15, p = 0.01)]. Full HIV-disclosure increased from 41.6% at inclusion to
74.1% after 24 months. After 24 months of follow-up, six (2.9%) died, eight (3.8%) were
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lost to follow-up, and four (1.9%) were transferred out. Overall, 73.7% did not progress
to the WHO-AIDS stage, and 62.7% had a CD4 count above (±10%) of the baseline
value (48.6% in Abidjan vs. 69.0% in Lomé, p < 0.001). Among the 83.7% with VL
measurement, 48.8% were virologically suppressed (Abidjan: 45.4%, Lomé: 52.5%,
p < 0.01). The 24-month combined outcome was favorable for 45% (29.6% in Abidjan
and 61.4% in Lomé, p < 0.01). Adjusted for baseline variables, the 24-month outcome
was worse in Lomé in those who had been disclosed for >2 years compared to those
who had not been disclosed to [aOR = 0.21, 95% CI (0.05–0.84), p = 0.03].
Conclusions: The frequency of HIV-disclosure improved over time and differed across
countries but remained low amongWest African APHIV. Overall, the 24-month outcomes
were poor. Disclosure before the study was a marker of a poor 24-month outcome in
Lomé. Context-specific responses are urgently needed to improve adolescent care and
reach the UNAIDS 90% target of virological success.
Keywords: adolescents, HIV, disclosure, retention, West-Africa
INTRODUCTION
Access to antiretroviral therapy (ART) in sub-Saharan Africa
has significantly expanded since 2004 (1). As a result, children
living with perinatally-acquired HIV are now growing up into
adolescence. The critical period of adolescence is characterized
by biological and psychosocial changes in a context where HIV
disease is turning into a chronic condition (2, 3). Globally,
1.8 million adolescents aged 10–19 years were living with HIV
in 2017 (4). Sub-Saharan Africa is the most impacted region,
accounting for 84% of the adolescents living with HIV (ALHIV)
(5–7); adolescent girls accounted for three-quarters of all new
HIV infections among adolescents in 2018 (8). HIV/AIDS was
the leading cause of death amongst adolescents in this region in
2016 (9). Among the 23 African priority countries, the estimated
AIDS-related deaths were 24,000 (17,000–33,000) in adolescents
aged 10–14 years and 25,000 (18,000–34,000) in those aged 15–
19 years in 2017 (10). Despite the progress achieved in pediatric
HIV care, attention must be paid to this expanding population
of adolescents living with either perinatally or non-perinatally
acquired HIV, since it is estimated that new HIV infections in
adolescents will increase 13% annually by 2030 in Africa (11, 12).
This is particularly true in West and Central Africa, which
has recorded a 35% increase in the annual number of AIDS-
related deaths among adolescents aged 15–19 years from 2010 to
2016 (13).
Since 2015, universal ART is recommended by the WHO
(14). Compared to adults or younger children, adolescents
living with perinatally acquired HIV (APHIV) experience a
higher morbidity and mortality and lower rates of virological
suppression on ART (3, 15–17). This is most likely related to the
delayed access to HIV diagnosis and ART in childhood, lack of
timely HIV-disclosure while growing-up, with poor medication
adherence in a context of prolonged ART, poor retention in
care, explained by individual, social, and structural barriers
(7, 18–22). Transition to adult care also remains a vulnerable
step in ALHIV care (23, 24). All these factors contribute to
delaying the UNAIDS’ 90-90-90 targets in the ALHIV cascade of
care (25).
However, a timely HIV-disclosure in APHIV is a crucial
step to motivate ART adherence and to achieve these 90-90-90
UNAIDS targets (22, 25). Full disclosure of an HIV diagnosis
includes naming HIV/AIDS and providing information about
care and the modes of HIV transmission (22). Unfortunately,
a large proportion of APHIV diagnosed during their infancy
remains unaware of their HIV-positive status while growing up.
In many West African pediatric clinical sites, even if children or
adolescents are onART, healthcare providers and caregivers delay
HIV disclosure because of cultural factors and lack of national
guidance (22). Also, caregivers are not ready and fear that the
process will lead to disclosing a family secret with subsequent
stigma (26–29). According to a previous review, 1.7–41% of
children and ALHIV in low- and middle-income countries have
received full disclosure of their HIV-positive status (30). In West
Africa, less than a third of APHIV knew their HIV status in
2011, and the HIV disclosure process often occurred late after the
WHO-recommended age of 12 years (31, 32). Data suggests that
an earlier full HIV disclosure could improve ALHIV outcomes
through improved ART adherence, retention in care, and slower
disease progression (29, 33, 34).
The prospective monitoring of the HIV disclosure process in
APHIV is crucial to understand their clinical, immunological,
and virological long-term outcomes. To better document the
outcomes of APHIV in West Africa, the COHADO (“COHort
of ADOlescents living with HIV”) sub-cohort, as part of
the West African International epidemiologic Database to
Evaluate AIDS (IeDEA) pediatric cohort Collaboration, was
launched in 2015 in two sites of the West African IeDEA
pediatric cohort in Lomé (Togo) and Abidjan (Côte d’Ivoire).
This study is aimed to better document HIV disclosure
frequency and process over 24 months of follow-up; and to
assess the association of HIV disclosure with the 24-month
health outcomes among APHIV since their inclusion in the
COHADO cohort.
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METHODS
Study Design
The IeDEA pediatric West African Database to evaluate AIDS
(pWADA) is an international multicentric prospective cohort as
part of the IeDEA global pediatric collaboration (https://www.
iedea.org/), supported by the US National Institutes of Health
since 2006, to describe HIV epidemiology trends and evaluate
HIV outcomes using large patient-level observational databases.
It includes children and adolescents living with HIV from 11
pediatric clinical centers in seven West African countries (Benin,
Burkina Faso, Côte d’Ivoire, Ghana, Mali, Senegal, and Togo) and
is aimed at addressing HIV/AIDS research questions regarding
HIV care and outcomes in children and adolescents living with
HIV in West Africa (35). Nested in pWADA, the COHADO
prospective cohort was a pilot study aimed to explore the
feasibility of collecting prospective data to specifically focus on
APHIV issues such as the HIV-disclosure process and behavioral
issues in two pilot sites, Lomé (Togo) andAbidjan (Côte d’Ivoire),
between 2015 and 2017.
Settings and Study Population
The COHADO cohort included APHIV from the pediatric
pWADA active file of the Teaching Hospital of Yopougon
(Abidjan, Côte d’Ivoire) and the Sylvanus Olympio Teaching
Hospital (Lomé, Togo). In accordance with the national
guidelines, APHIV followed-up in these sites are typically seen
in medical consultation on a quarterly basis. CD4 count were
measured 6-monthly, and, since 2016, viral load is monitored on
a yearly basis.
Between January and November 2015, ART-treated ALHIV
aged 10–19 years, included in HIV care before the age of 10 years
(as a proxy of perinatal infection in the absence of a documented
mode of transmission) and followed up in the two participating
sites, were invited to enroll in the study.
Ethics Approval and Consent to Participate
This study has received authorizations from the health ministries
and national ethics committee of Togo and Côte d’Ivoire. All
the participants and their caregivers gave their written informed
consent to participate in the COHADO cohort. A specific consent
form was adapted to the adolescents’ awareness of their HIV
status to avoid any unintentional disclosure.
Data Collection
Study-specific data including living and schooling conditions,
parents’ vital status, access to running water, access to electricity,
disclosure (at baseline and during follow-up), and disclosure
process were recorded using standardized questionnaires which
are assessed yearly. Other sociodemographic, clinical, and
therapeutic data were extracted from medical records and
the IeDEA pediatric central database. Since the causes of
death were not documented, we hypothesized that all deaths
were HIV-related.
The word HIV was not mentioned in the adolescent
questionnaires to avoid any accidental HIV disclosure to the
adolescent during the interview. Data on the HIV disclosure
process (disclosure status, date of full disclosure if delivered over
the cohort period, person in charge of disclosure) were collected
from the parents/legal guardian, rather than the adolescents
themselves. HIV disclosure was defined as full disclosure when
the adolescent was specifically told that he or she has HIV/AIDS
and he/she knew the care and modes of transmission (22).
Treatment adherence was evaluated by the counselor using the
ratio between the number of pills prescribed and the number of
pills missed in the last days preceding the visit and declared by
the adolescent.
Data Analysis
Baseline was defined as the date of inclusion in the
COHADO cohort.
First, among the eligible APHIV, we compared the baseline
characteristics of those who were included vs. those who were
not included in the study, using median values with interquartile
ranges (IQR) for continuous variables and proportions for
categorized variables, overall and by site. Full HIV disclosure
was assessed at baseline, and then over the 24-month follow-up
period. APHIV were classified at 24 months as not HIV-disclosed
to, disclosed to during the past 24 months (after inclusion in
COHADO), or HIV-disclosed to for more than 2 years, before
inclusion in the COHADO cohort (in this group, the date of
disclosure was often not recorded).
Second, we compared the baseline characteristics of APHIV
according to their 24-month HIV disclosure status. Among those
who were unaware of their HIV status at inclusion, we analyzed
the factors associated with HIV disclosure during the follow-up
period using a logistic regression. The person involved in the
HIV disclosure process, timing of HIV disclosure regarding ART
initiation, and reasons for non-disclosure were described.
Third, we described the 24-month clinical, immunological,
and virological outcomes both individually and as a combined
outcome. The combined 24-month outcome was measured by
combining multiple criteria: (i) vital status [alive, died, lost to
follow-up (defined last clinical contact>6months, and for whom
transfer, or vital status was unknown at database closure)]; (ii)
WHO AIDS stage progression since baseline [WHO Clinical
staging of HIV is a symptomatic classification of HIV that
ranges according to increasing severity from 1 to 4 (36)]; (iii)
immunological criteria (% of CD4 cell count difference since
baseline); and (iv) virological criteria (HIV viral load measured).
An unfavorable outcome was defined when at least one of the
following events occurred: death, loss to follow-up, progression
to AIDS clinical stage during the study period, a CD4 count
decrease >10% compared to baseline, or a detectable viral load
>50 copies/mL. If one of the evaluation criteria was missing to
determine this combined outcome, adolescents were nevertheless
classified using the remaining documented criteria. A favorable
24-month outcome was therefore defined as none of the above
events occurring over the study period. Correlates of a 24-month
favorable combined outcome, according to the HIV disclosure
status and other baseline variables, were described using a full
logistic regression model. The co-variable that was significantly
associated with a 20% threshold in the univariate analysis were
included in the adjusted logistic regression model accounting
for country-specific practices regarding HIV-disclosure. We also
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performed a sub-analysis investigating the correlates of a 24-
month favorable combined outcome in a sub-population of
APHIV who had their viral load data available at 24 months.
Model fits were checked graphically using Pearson residuals.
Categorical variables were described using counts and
percentages and compared using the Pearson’s Chi2 tests (or
Fisher’s Exact test if adapted). Continuous variables were
described by median and interquartile ranges (IQR) and
compared using the Wilcoxon-Mann-Whitney test. All analyses
were performed using STATA 14.2 (Statacorp, College Station,
TX, USA), with a 5% significance level.
RESULTS
Selection and Inclusion of APHIV in the
COHADO Cohort
From January to November 2015, 511 APHIV visited the sites
of Abidjan and Lomé. Among them, a total of 209 (40.9%)
APHIV were offered enrollment in COHADO and gave their
consent (Figure 1). Reasons for not being included were mainly
due to either parent and APHIV refusal or low availability of
health care workers to enroll in the study, due to work overload.
This was significantly more observed in Abidjan compared to
Lomé (Table 1). ALHIVwho were included in COHADO did not
differ from those who were not included, in terms of sex, age,
and immunological status distributions at baseline. However, at
inclusion, there were significantly higher rates of missing data for
the WHO AIDS clinical staging and viral load among those who
were not included compared to those who were included in the
COHADO cohort (Table 1).
Baseline Characteristics
Baseline characteristics are presented in Table 2. Among the 209
APHIV included, 108 (52%) lived in Abidjan. Overall, 114 (55%)
were females and the median age was 13 years (IQR: 11–15).
APHIV were significantly older in Abidjan (14 years) compared
to Lomé (12 years, p = 0.01). Median ART duration prior to
inclusion in the COHADO cohort was 6 years (IQR: 4–10), and
it was significantly longer in Abidjan [9, IQR: (7–11)] compared
to Lomé [5, IQR: (2–6)] (p < 0.01). Only 23.9% of the cohort
lived with both their biological parents. Most APHIV (89.9%)
were from urban areas, 97.1% had access to electricity, and 62.7%
had access to running water at home.
Overall, 17.2% had already reached the WHO AIDS stage 4
at baseline. This proportion was significantly higher in Lomé
(32.7%) compared to Abidjan (2.8%) (p < 0.01). Regarding
ART, 81.3% were receiving a NNRTI-based regimen, and 56.4%
of APHIV showed good adherence to ART, as defined in
the Methods section. Only 29.6% of APHIV had a viral load
measurement; of whom, 3.2% with virological suppression (<50
cp/mL). At baseline, 41.6%were already fully HIV-disclosed. This
proportion was significantly higher in Abidjan (57.4%) compared
to Lomé (24.8%, p < 0.01).
FIGURE 1 | Flow chart of the 209 APHIV participant in the COHADO Cohort, IeDEA-pWADA, 2015.
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TABLE 1 | Characteristic of eligible adolescents living with perinatally-acquired HIV (APHIV) included in the COHADO cohort compared to those who were not included,
during the inclusion period in Abidjan (Côte d’Ivoire), Lomé (Togo), IeDEA-pWADA, 2015–2017.
Total Not included in COHADO Included in COHADO P- Value
N = 511 (%) N = 302 (%) N = 209 (%)
Site, n (%) <0.01a
Abidjan (Côte d’Ivoire) 371 (72.6) 263 (87.1) 108 (51.7)
Lomé (Togo) 140 (27.4) 39 (12.9) 101 (48.3)
Sex, n (%) 0.61a
Males 239 (46.8) 144 (47.7) 95 (45.4)
Females 272 (53.2) 158 (52.3) 114 (54.6)
Age in years, median [IQR] 13 [11–15] 14 [12–16] 13 [11–15] 0.06c
Age initiation ART,
median [IQR] 7[4–9] 6[4–9] 7[4–10] 0.12c
WHO clinical stage <0.01b
1, 2, 3 380 (74.4) 207 (68.5) 173 (82.8)
4 (AIDS) 43 (8.4) 7 (2.3) 36 (17.2)
Missing 88 (17.2) 88 (29.4) 0 (0.0)
Virological suppression at last, n (%)
(Viral load <50 cp/mL) <0.01b
Yes 34 (6.7) 32 (10.6) 2 (1.0)
No 190 (37.2) 130 (43.0) 60 (28.7)
Missing 287 (56.1) 140 (46.4) 147 (70.3)
CD4, median [IQR] 483 [258–701] 487 [277–678] 534 [278–798] 0.76c
aChi2 test; bFisher’s exact test; cWilcoxon-Mann-Whitney test.
HIV Disclosure Characteristics and
Process
Among the 209 APHIV enrolled, 122 (58.4%) were not informed
of their HIV status at inclusion in the COHADO cohort, while
they were aged of 12 years in median. Questioned about the
reasons of non-disclosure at inclusion, parents/legal guardians
declared fear of the adolescent’s reaction (75.0%), and fear of
HIV status disclosure to others (69.1%) were the most frequent
reasons. Other reasons included the young age of APHIV (52.9%)
and the fact that their parents were not prepared (35.3%).
At the 24-month endpoint, 87 (41.6%) APHIV were informed
of their HIV status before inclusion, 68 (32.5%) were disclosed to
during follow-up, and 54 (25.8%) were still not aware. Baseline
characteristics of APHIV according to the HIV disclosure status
at the endpoint are presented in Table 3. Overall, 74.1% were
fully HIV-disclosed at the 24-month endpoint (+43.9% relative
increase compared to baseline, p < 0.01).
Among the 122 APHIV who were unaware of their HIV
status at inclusion, those who were informed of their HIV
status at the end of follow-up tended to have a lower CD4
cell count at baseline compared to those who were not HIV-
disclosed to (Table 3). Compared with APHIV who were not
HIV-disclosed, APHIVwhowere HIV-disclosed during the study
were significantly older [13 years at baseline IQR (11–14) vs. 11
years IQR (10–12), p < 0.01], on ART for a shorter period of
time [5 years IQR (2–8) vs.0 7 years IQR (5–9), p = 0.03], and
mostly from Lomé (78 vs. 43%, p > 0.01). Adjusted for covariates
(sex, education level, residential environment, person with whom
APHIV lives, baseline clinical AIDS stage, CD4 cell count, age,
and ART duration), APHIV from Lomé were significantly more
likely to be HIV-disclosed during the study compared to those
from Abidjan [adjusted odds ratio (aOR): 15.2, 95% CI (3.12–
73.9)] (Table 4).
Among the 155 APHIV who were fully HIV-disclosed to by
24 months, both parents (40.7%) and psychologists (54.2%) were
the most involved in the HIV disclosure process, doctors were
involved in the process for only 5.2% of APHIV, and counselors
for 1.9% (Table 5).
24-Month Health Outcomes
By 24 months, six APHIV had died (2.9%) and eight
were lost to follow-up (3.8%). Among the remaining
APHIV followed-up, 71.7% (150/197) were still on a
NNRTI-based regimen.
By 24 months, 99.0% (207/209) of the APHIV had
their clinical data available, of whom, 54.5% were classified
as having an “unfavorable” outcome; 99.0% (207/209) had
their immunological data available, of whom, 55.0% were
classified as “unfavorable”; and 83.7% (175/209) had their
virological data available, of whom, 61.1% were classified as
“unfavorable.” Altogether, 175 (83.7%) had their data available
for all components used to build the combined outcome
at 24 months and 34 (16.3%) had at least their viral load
data missing.
The proportion of APHIV who were HIV-disclosed during
the follow-up period was higher in Lomé (52.5%) than in
Abidjan (13.9%) (p < 0.01) (Table 6). Among the 209 APHIV,
the 24-month combined health outcome was favorable for 45%
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TABLE 2 | Baseline characteristics of the 209 adolescents living with perinatally-acquired HIV included in the COHADO cohort according to sites, Abidjan (Côte d’Ivoire),
Lomé (Togo) IeDEA-pWADA, 2015–2017.
Total Abidjan, Côte d’Ivoire Lomé, Togo P-Valuea
N = 209 (%) N = 108 (%) N = 101 (%)
Sex n (%) 0.25
Males 95 (45.4) 45 (41.7) 50 (49.5)
Females 114 (54.6) 63 (58.3) 51 (50.5)
HIV disclosure performed, n (%) <0.01
Yes 87 (41.6) 61 (57.4) 25 (24.8)
No 122 (58.4) 45 (42.6) 76 (75.2)
Education level, n (%) 0.01
Primary school 80 (38.3) 31 (28.7) 49 (48.5)
Middle schools 103 (49.3) 61 (56.5) 42 (41.6)
High schools 26 (12.4) 16 (14.8) 10 (9.9)
Residential environment, n (%) 0.91
Urban 187 (89.9) 96 (88.9) 91 (90.1)
Rural 22 (10.1) 12 (11.1) 10 (9.9)
Electricity access, n (%) 0.43b
Yes 203 (97.1) 106 (98.1) 97 (96.0)
No 6 (2.9) 2 (1.9) 4 (4.0)
Running water access, n (%) <0.01
Yes 131 (62.7) 101 (93.5) 30 (29.7)
No 78 (37.3) 7 (6.5) 71 (70.3)
Living with, n (%) 0.65
Both parents 50 (23.9) 27 (25.0) 23 (22.8)
Only one parent 93 (44.5) 50 (46.3) 43 (42.6)
Other family member 66 (31.6) 31 (28.7) 35 (34.6)
Orphanhood, n (%) 0.03
No 91 (43.5) 44 (40.7) 47 (46.5)
One parent 91 (43.5) 55 (50.9) 36 (35.6)
Two parents 27 (13.0) 9 (8.4) 18 (17.8)
WHO clinical stage, n (%) <0.01
1, 2, 3 173 (83.8) 105 (97.2) 68 (67.3)
4 (AIDS) 36 (17.2) 3 (2.8) 33 (32.7)
ART regimen, n (%) 0.48
2 NRTI+1NNRTI 168 (81.2) 88 (83.0) 80 (79.2)
2 NRTI+1PI 39 (18.8) 18 (17.0) 21 (20.8)
Good ART adherence†, n (%) <0.01b
Yes 118 (56.4) 57 (52.7) 61 (51.6)
No 57 (27.3) 24 (22.2) 33 (32.6)
Missing 34 (16.3) 27 (25.0) 7 (6.9)
Virological suppression, n/N (%)
(viral load <50 cp/mL) <0.01
Yes 2/62 (3.2) 0/53 (0.0) 2/9 (22.2)
No 60/62 (96.8) 53/53 (100.0) 7/9 (77.8)
CD4 cell count/mm3, median [IQR]
521[281–757] 540[314–753] 484[271.5–760] 0.71c
Age at inclusion in years, median [IQR]
13[11–15] 14[12–15] 12[11–15] 0.01c
ART duration in years, median [IQR]
6[4–10] 9[7–11] 5[2–6] <0.01c
Age at ART initiation, median [IQR]
7[4–10] 5[3–8] 9[6–11] <0.01c
aChi2 test; bFisher’s exact test; cWilcoxon-Mann-Whitney test. †More than 95% of planned doses taken. ART, Antiretroviral therapy.
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TABLE 3 | Baseline characteristics of the 209 APHIV included according to HIV-serostatus disclosure at 24-month, in the COHADO cohort, Abidjan (Côte d’Ivoire), Lomé
(Togo), IeDEA-pWADA, 2015–2017.
Total












N = 54 (%)
P-Valuea
Sex, n (%) 0.64
Males 95 (45.4) 37 (42.5) 34 (50.0) 24 (44.4)
Females 114 (54.6) 50 (57.5) 34 (50.0) 30 (55.6)
Site, n (%) <0.01
Abidjan (Côte-d’Ivoire) 108 (51.7) 62 (71.3) 15 (22.1) 31 (57.4)
Lomé (Togo) 101 (48.3) 25 (28.7) 53 (77.9) 23 (42.6)
Age at baseline in years, median [IQR] 13[11–15] 15[14–17] 12[11–14] 11[10–12] <0.01c
Orphanhood, n (%) 0.36
No 91 (43.5) 31 (35.6) 31 (47.1) 28 (51.6)
One parent 91 (43.5) 43 (49.4) 27 (39.7) 21 (38.9)
Two parents 27 (13.0) 13 (14.9) 9 (13.2) 5 (9.3)
Education level <0.01b
Primary school 80 (38.3) 14 (16.1) 31 (45.6) 35 (64.8)
Middle schools 103 (49.3) 49 (56.3) 35 (51.5) 19 (35.2)
High schools 26 (12.4) 24 (27.6) 2 (2.9) 0 (0.0)
Running water access <0.01
Yes 131 (62.7) 67 (77.0) 32 (47.1) 32 (59.3)
No 78 (37.3) 20 (22.9) 36 (52.9) 22 (40.7)
Electricity access, n (%) 0.76
No 6 (2.9) 3 (3.4) 1 (1.5) 2 (3.7)
Yes 203 (97.1) 84 (96.6) 67 (98.5) 52 (96.3)
Residential environment 0.53
Urban 187 (89.5) 77 (88.5) 63 (92.6) 47 (87.1)
Rural 22 (10.5) 10 (11.5) 5 (7.4) 7 (12.9)
Living with 0.94
Both parents 50 (23.9) 19 (21.8) 18 (26.5) 13 (24.1)
Only one parent 93 (44.5) 38 (43.7) 30 (44.1) 25 (46.3)
Other family member 66 (31.6) 30 (34.5) 20 (29.4) 16 (29.6)
WHO clinical stage, n (%) 0.41b
1, 2, 3 173 (82.8) 73 (83.9) 53 (77.9) 47 (87.1)
4 (AIDS) 36 (17.2) 14 (16.1) 15 (22.1) 7 (12.9)
Virological suppression (n = 62),
(Viral load <50 cp/mL) 0.68b
Yes 2 (3.2) 1 (2.9) 0 (0.0) 1 (6.3)
No 60 (97.8) 34 (97.1) 11 (100.0) 15 (93.7)
CD4 cell count/mm3, median [IQR]
521[281–758] 492[225–734] 507[262–850] 548[416–843] 0.08c
aChi2 test; bFisher’s exact test;cKruskal-Wallis test.
of APHIV overall. This proportion was significantly higher
in Lomé (61.4%) compared to Abidjan (29.6%, p < 0.01)
(Table 6).
Table 7 presents the correlates of a 24-month favorable
combined health outcome in APHIV. In the univariate analysis,
we found that APHIV from Lomé [vs. Abidjan, OR = 3.77, 95%
CI (2.12–6.71), p < 0.01] and those without access to running
water [vs. with access to running water, OR = 2.09, 95% CI
(1.18–3.70), p = 0.01] were significantly more likely to have a
favorable outcome. Age at inclusion was not associated with the
outcome. Longer treatment duration reduced the probability of
having a 24-month favorable outcome [OR = 0.90 per year, 95%
CI (0.83–0.97), p= 0.01].
There was a significant interaction between HIV disclosure
and country. In the multivariate analyses adjusted for sex, access
to running water, residential environment, and being orphan
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TABLE 4 | Correlates of HIV disclosure at 24-month among the 122 APHIV not disclosed at inclusion, in the COHADO cohort, Abidjan (Côte d’Ivoire), Lomé (Togo),
IeDEA-pWADA, 2015–2017.
Univariate analysis Multivariate analysis
Total
N = 122 (%)
HIV
status disclosed
N = 68 (%)
HIV status not
disclosed
N = 54 (%)
P-Valuea Full model
aOR (95% CI) p-value
Sex, n (%) 0.54
Males 58 (47.5) 34 (50.0) 24 (44.4) 1.00 — —
Females 64 (52.5) 34 (50.0) 30 (55.6) 1.02 (0.41–2.51) 0.96
Site, n (%) <0.01
Abidjan (Côte-d’Ivoire) 46 (37.7) 15 (22.1) 31 (57.4) 1.00 — —
Lomé (Togo) 76 (62.3) 53 (77.9) 23 (42.6) 15.2 (3.12–73.9) <0.01
Orphanhood, n (%) 0.76
No 60 (49.2) 32 (47.1) 28 (46.5)
One parent 48 (39.3) 27 (39.7) 21 (35.6)
Two parents 14 (11.5) 9 (13.2) 5 (17.8)
Education level 0.05
Primary school 66 (54.1) 31 (45.6) 35 (64.8) 1.00 — —
Middle schools 54 (44.3) 35 (51.5) 19 (35.2) 1.42 (0.49–4.16) 0.51
High schools 2 (1.6) 2 (2.9) 0 (0.0) 1.00 — —
Running water access 0.18
Yes 64 (52.4) 32 (47.1) 32 (59.3) 1.00 — —
No 58 (47.5) 36 (52.9) 22 (40.7) 0.51 (0.11–2.12) 0.35
Electricity access, n (%) 0.58
Yes 119 (97.5) 67 (98.5) 52 (96.3)
No 3 (2.46) 1 (1.5) 2 (3.7)
Residential environment 0.36
Urban 110 (90.2) 63 (92.6) 47 (87.1) 1.00 — —
Rural 12 (9.8) 5 (7.4) 7 (12.9) 0.62 (0.11–3.27) 0.58
Living with 0.95 0.93
Both parents 31 (25.4) 18 (26.5) 13 (24.1) 1.00 — —
Only one parent 55 (45.1) 30 (44.1) 25 (46.3) 1.17 (0.37–3.67) 0.78
Other family member 36 (29.5) 20 (29.4) 16 (29.6) 0.99 (0.27–3.61) 0.98
WHO clinical stage, n (%) 0.19b
1, 2, 3 100 (81.9) 53 (77.9) 47 (87.1) 1.00 — —
4 (AIDS) 22 (18.1) 15 (22.1) 7 (12.9) 0.44 (0.10–1.84) 0.26
CD4 cell count/mm3, median [IQR]
546[305–843] 508[262–850] 548[416–843] 0.19 c 0.99 (0.99–1.00) 0.88
Virological suppression (n = 27),
(Viral load <50 cp/mL) 1.00
Yes 1 (3.7) 0 (0.0) 1 (6.3)
No 26 (96.3) 11 (100.0) 15 (93.7)
Age at inclusion in years, median [IQR]
12[11–13] 13[11–14] 11[10–12] <0.01c 1.86 (1.31–2.63) <0.01
Age at ART initiation, median [IQR]
6[4–9] 8[4–11] 5[3–7] <0.01c
ART duration in years, median [IQR]
6[3–9] 5[2–8] 7[5–9] 0.03c 0.96 (0.80–1.15) 0.69
aChi2 test; bFisher’s exact test; cWilcoxon-Mann-Whitney test.
or not, HIV disclosure for >2 years significantly reduced the
probability of having a favorable 24-month outcome compared
to those who were not HIV-disclosed in Lomé [Disclosed > 2
years: aOR= 0.21, 95% CI (0.05–0.84), p= 0.03], while there was
no significant association in Abidjan (Table 7). Access to running
water and ART duration were the confounding factors that
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TABLE 5 | Characteristics of the HIV disclosure modalities to the 155 adolescents living with perinatally-acquired HIV disclosed at 24 months by sites in the COHADO
cohort, IeDEA-pWADA, 2015–2017.
Total Abidjan, Côte d’Ivoire Lomé, Togo
N = 155 (%) N = 77 (%) N = 78 (%)
Person involved in HIV disclosure, n (%)
Mother 41 (26.5) 30 (43.5) 11 (14.3)
Father 22 (14.2) 18 (26.1) 4 (5.2)
Doctor 8 (5.2) 6 (8.7) 2 (2.6)
Psychologist 84 (54.2) 25 (36.2) 59 (76.6)
Counselor 3 (1.9) 0 (0.0) 3 (2.1)
Other (Family or association members) 3 (1.9) 0 (0.0) 3 (2.1)
Disclosure performed before ART initiation
Yes 13 (8.4) 6 (7.8) 7 (8.4)
No 133 (85.8) 64 (83.1) 69 (88.5)
Unknown 9 (5.8) 7 (9.1) 2 (2.6)
TABLE 6 | 24-month component and combined outcomes of the 209 adolescents living with perinatally-acquired HIV included, by sites in the COHADO cohort,
IeDEA-pWADA, 2015–2017.
Total Abidjan, Côte d’Ivoire Lomé, Togo P-Valuea
N = 209 (%) N = 108 (%) N = 101 (%)
HIV-disclosure performed, n (%) <0.01
No 54 (25.9) 31 (28.7) 23 (22.7)
Yes (Since ≤2 years) 68 (32.5) 15 (13.9) 53 (52.5)
Yes (Since >2 years) 87 (41.6) 62 (57.4) 25 (24.8)
Follow-up, n (%) 0.18b
Died 6 (2.9) 4 (3.7) 2 (2.0)
Lost to follow-up 8 (3.8) 3 (2.8) 5 (4.9)
Transferred out 4 (1.9) 4 (3.7) 0 (0.0)
Alive & follow-up 191 (91.4) 97 (89.8) 94 (93.1)
Progression to AIDS WHO
Stage during the study period, n (%) <0.01b
Yes 7 (3.3) 5 (4.6) 2 (2.0)
No 154 (73.7) 91 (84.2) 63 (62.4)
Already AIDS WHO at inclusion 36 (17.3) 3 (2.8) 33 (32.7)
Died, LTFU, transferred out, missing 12 (5.7) 9 (8.3) 3 (2.9)
CD4 count decrease ≥ baseline
value (±10%), n (%) <0.01
Yes 76 (36.3) 55 (51.4) 21 (21.0)
No 131 (62.7) 52 (48.6) 79 (69.0)
Missing 2 (1.0) 1 (1.0) 1 (1.0)
Viral load detectable at 24-month
(>50 cp/mL) 0.01
Yes 73 (34.9) 56 (51.8) 17 (16.8)
No 102 (48.8) 49 (45.4) 53 (52.5)
Missing 34 (16.3) 3 (2.8) 31 (30.7)
Combined outcome†, n (%) <0.01
Unfavorable 115 (55.0) 76 (70.4) 39 (38.6)
Favorable 94 (45.0) 32 (29.6) 62 (61.4)
aChi2 test; bFisher’s exact test.
†Unfavorable combined outcome at 24 months: death or progression to AIDS during the study period or CD4 count decrease >10% compared to baseline or detectable viral load.
Favorable outcome: none of the outcomes defined above notified.
The bold values are statistically significants with a p value < 5%.
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TABLE 7 | Correlates of a favorable combined 24-month health outcome (definition: Table 5) of the 209 APHIV included, in the COHADO, IeDEA-pWADA, 2015–2017.





n = 115 (%) n = 94 (%) OR (95% CI) p-value aOR (95% CI) p-value
HIV-Disclosure 0.17
No 27 (23.5) 27 (28.7) 1.00 — — — — —
Yes (Since ≤2 years) 35 (30.4) 33 (35.1) 0.94 (0.46–1.92) 0.87 — — —
Yes (Since >2 years) 53 (46.1) 34 (36.2) 0.64 (0.32–1.27) 0.20 — — —
Site
Abidjan, Côte-d’Ivoire 76 (66.1) 32 (34.1) 1.00 — — — — —
Lomé, Togo 39 (33.9) 62 (65.9) 3.77 (2.12–6.71) <0.01 — — —
HIV Site*Disclosure (exploratory Interaction) <0.01 <0.01
Abidjan, Côte-d’Ivoire
HIV not disclosed 23 (11.0) 8 (3.8) 1.00 — — 1.00 — —
HIV disclosed ≤ 2years 13 (6.2) 2 (0.9) 0.44 (0.08–2.40) 0.34 0.34 (0.06–1.92) 0.22
HIV disclosed >2years 40 (19.1) 22 (10.5) 1.58 (0.61–4.12) 0.35 1.44 (0.53–3.87) 0.47
Lomé, Togo
HIV not disclosed 4 (1.9) 19 (9.1) 1.00 — — 1.00 — —
HIV disclosed ≤2 years 22 (10.5) 31 (14.8) 0.29 (0.08–0.99) 0.04 0.30 (0.87–1.04) 0.05
HIV disclosed >2 years 13 (6.2) 12 (5.7) 0.19 (0.05–0.73) 0.02 0.21 (0.05–0.84) 0.03
Sex
Males 48 (41.7) 47 (50.0) 1.00 — — 1.00 — —
Females 67 (58.3) 47 (50.0) 0.71 (0.41–1.23) 0.23 0.76 (0.41–1.41) 0.39
Baseline ART regimen, n (%)
2 NRTI+1PI 19 (33.9) 20 (21.3) 1.00 — —
2 NRTI+1NNRTI 94 (66.1) 74 (78.7) 0.75 (0.37–1.50) 0.42
Education level 0.63
Primary school 41 (35.6) 39 (41.5) 1.00 — —
Middle schools 60 (52.2) 43 (45.7) 0.75 (0.41–1.35) 0.34
High schools 14 (12.2) 12 (12.8) 0.90 (0.37–2.18) 0.81
Running water access
Yes 81 (70.4) 50 (53.2) 1.00 — — 1.00 — —
No 34 (29.6) 44 (46.8) 2.09 (1.18–3.70) 0.01 0.60 (0.25–1.45) 0.26
Electricity access, n (%)
Yes 112 (97.4) 91 (96.8) 1.00 — —
No 3 (2.6) 3 (3.2) 1.23 (0.24–6.24) 0.80
Residential environment
Urban 100 (86.9) 87 (92.6) 1.00 — — 1.00 — –
Rural 15 (13.1) 7 (7.4) 0.53 (0.21–1.37) 0.19 0.64 (0.23–1.81) 0.40
Living with 0.35
Both parents 25 (21.7) 25 (26.6) 1.00 — — 1.00 — —
Only one parent 49 (42.6) 44 (46.8) 0.89 (0.45–1.78) 0.75 0.99 (0.45–2.15) 0.98
Other family member 41 (35.7) 25 (26.6) 0.60 (0.28–1.28) 0.19 0.56 (0.24–1.29) 0.17
Age at baseline, median [IQR] 13 [11–15] 13[11–15] 0.96 (0.86–1.07) 0.54
ART duration in years, median [IQR] 8[4–10] 7[4–10] 0.90 (0.83–0.97) 0.01 0.98 (0.89–1.09) 0.52
OR: Odds Ratio aOR:adjusted Odds Ratio. The bold values are statistically significants with a p value < 5%.
were no longer significant in the adjusted analysis. A sensitivity
analysis investigating the correlates of a 24-month favorable
combined outcome restricted to adolescents with available data
for all criteria was run, but this did not change the main
results (data not shown).
DISCUSSION
To our knowledge, this is the first cohort to report a snapshot of
the clinical, immunological, and virological outcomes of APHIV
measured over 24 months in relation to HIV disclosure in two
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West African pilot sites contributing to the IeDEA West Africa
collaboration. We made several key findings highlighting the
field reality of the evolving trends of APHIV care from 2015
to 2017. First, full HIV disclosure status to APHIV increased
from 46 to 74% after 24 months of follow-up, but we still found
that one in four APHIV remained not formally disclosed to
by the time of the endpoint, while they were all aged above
13 years. Second, unlike caregivers and psychologists, doctors
and counselors have a very little involvement in the disclosure
process. Third, although access to viral load increased from 30%
at inclusion to 84% after 24 months, still, 16% had no viral load
measurement. Fourth, we found that after 24 months of follow-
up, the cumulative death rate was high, close to 3%, and only 45%
of APHIV had a favorable 24-month combined outcome, while
77.5% were still receiving a NNRTI-based regimen. Finally, in the
adjusted analysis of the correlates of a combined health outcome,
we found that being HIV-disclosed before the inclusion was a
significant marker of a worse outcome in Lomé, while there was
no association found in Abidjan.
Although the frequency of ALHIV fully HIV-disclosed differs
among African studies, it remains low overall, ranging from
16 to 39% (37–42). In our study, we found that only 46.1%
knew their HIV status at baseline and 74.2% by 24 months of
follow-up. Although this should be closer to 100% according
to the WHO recommendations, our result is higher than that
reported in previous studies, particularly in West Africa (26,
32, 43). In Ghana, two separate studies reported the proportion
of HIV disclosure to be 11.2% among children and adolescents
aged 8–14 years in 2009 and 44% among ALHIV aged 12–19
years in 2015 (26, 44). Furthermore, we observed an increase
in the HIV disclosure process over the 24-month follow-up
period. This is clearly visible in Lomé where the proportion
of APHIV disclosed increased from 24.8 to 77.2%. APHIV
from Lomé were more likely to be disclosed during the study,
due to the low disclosure rates at baseline, younger age, and
older age at ART initiation in this cohort. This increase could
indeed mainly be explained by the cohort effect, as adolescents
age over time, and age is one of the main factors of HIV
disclosure. However, in the COHADO context, this is also likely
the consequence of a 3-day training workshop on the HIV-
serostatus disclosure to ALHIV delivered in 2016, involving
HIV health professionals from all the IeDEA-pWADA sites
(45). West and Central African healthcare workers (doctors,
psychologists, and social workers) and four expert adolescents
living with HIV were invited to participate in a 3-day workshop
to promote and support the HIV disclosure process in pediatric
clinical sites. After sharing their own experiences about the HIV
disclosure process, participants identified barriers and facilitating
practices, including the participating adolescents’ suggestions.
A standardized disclosure process was then proposed to be
implemented in their different facilities. This workshop involved
the COHADO staff and may have changed the health care
workers’ perceptions, prompting their practices regarding HIV
disclosure. As we were not able to document the rate of HIV
disclosure before and after this workshop, we also acknowledge
that we cannot isolate the effect of age from the training
workshop effect to explain the HIV disclosure rate.
We found that few doctors are involved in the process of HIV
disclosure and tended to delegate the HIV disclosure practice
to other health care workers. Reasons for this included clinical
work overload or fear in doing it. Indeed, health care workers
face structural issues including limited human and technical
resources, whereas disclosure is a complex process which needs
time and training (22, 29). In 2018, there were too few counselors
working in our HIV-programs. Thus, when available in HIV
programs, psychologists are better trained to address mental
issues such as HIV-related stigma and taboo, and therefore, are
more involved in the HIV disclosure process. Consequently,
they have become the only health care workers in charge of the
full HIV disclosure process, but they are not always available
on a daily basis. In our study, HIV disclosure was fortunately
covered by psychologists, showing a privileged context. They
were trained to HIV disclosure and developed a space for a
better communication and a privileged relationship of trust with
adolescents, constituting a central component for the issue of
HIV disclosure. However, psychologists are scarce in resource-
limited pediatric HIV care settings. In a study exploring the
models of HIV disclosure in 180 HIV pediatric care sites, HIV
disclosure counseling was most often provided by counselors
(87% of sites), nurses (77%), physicians (74%), social workers
(68%), or other clinicians (65%) (46). More recently, peer-
educators have also been successfully involved. Therefore, we
feel that the whole staff should be trained and involved in
the HIV disclosure process with a multidisciplinary approach
and task-sharing. That approach should be set up at each
HIV program level to offer comprehensive care, including the
process of HIV status disclosure. It is important for national
and regional programs to locally tailor appropriate strategies
to improve disclosure practice, such as the training of a
multidisciplinary team on disclosure, as mentioned earlier (45).
Furthermore, caregivers are also unprepared for HIV disclosure
and fear of stigmatization. For many parents, their children
are too young or are not ready to receive HIV disclosure (27,
30, 47). The role and benefits of having caregivers involved
in the HIV disclosure process remain unclear. While some
studies have suggested that caregivers are in a much better
position to disclose the ALHIV status, others have reported
that according to ALHIV, health care workers are better placed
(48–50). Nevertheless, a better understanding of what refrains
caregivers to disclose to their child is important to support
them accordingly.
In our study, the 24-month cumulative death rate reached
3%.This is high but similar to that reported in other studies
conducted in ALHIV in sub-Saharan Africa, ranging 4–6% (34,
51). We also reported a sub-optimal virological response in our
population that is in line with the results reported in a previous
study conducted in Lomé in 2016, with high rates of virological
failure and drug resistance among APHIV (17). APHIV in
Lomé were in a significantly poorer clinical and immunological
condition at baseline compared to those from Abidjan, and
therefore, were more likely to reach a favorable 24-month
outcome. However, APHIV from Abidjan were significantly
more in virological failure than those from Lomé at baseline.
However, APHIV from Abidjan were significantly older (2 years
Frontiers in Pediatrics | www.frontiersin.org 11 June 2021 | Volume 9 | Article 582883
Dassi Tchoupa Revegue et al. HIV-Serostatus Disclosure in Adolescents
in median), and treated for a longer period, highlighting a cohort
effect in site differences. Although we were not able to document
the different HIV sub-types, we do not hypothesize that this
could explain the difference between the two sites. Our finding
highlights rather historical differences in the care practices and
resources available betweenWest African cities, which need to be
considered to adapt APHIV care delivery. Overall, only 45% of
APHIV had a favorable combined 24-month outcome which is
poor in terms of the quality of ART response. These outcomes
are observed in a context where close to 80% of APHIV were
receiving a NNRTI-based therapy at baseline, then, still 77.5%
after 24 months, reflecting a limited access to a second line
therapy common in West-Africa. In our study, the baseline ART
regimen was not associated with the 24-month outcome. This
is likely an indication bias in a context where those receiving a
PI-based regimen as a second line therapy where those failing
in ART.
Many studies have reported on how HIV disclosure improves
ALHIV clinical, immunological, and virological outcomes as well
as retention in care (29, 33, 34, 51, 52). The relationship between
the time of HIV disclosure and the 24-month outcome was
difficult to assess in our study because a substantial proportion
of APHIV had already been disclosed to before the inclusion in
the COHADO cohort with no documented HIV-disclosure date.
There was a statistically significant interaction between the site
andHIV disclosure timing, andwe present our results accounting
for this cohort effect. Indeed, ALHIV in Abidjan were older than
those from Lomé, HIV-disclosure practices were more active
during the follow-up in Lomé than in Abidjan, and ALHIV from
Lomé were at a more advanced stage of their HIV disease at
inclusion compared to those from Abidjan. We found that HIV
disclosure before inclusion in the study in Lomé significantly
reduced the odds of having a favorable 24-month outcome while
there was no association found in Abidjan. We interpret this
association by HIV-disclosure being the marker of an advanced
HIV disease that may have prompted the disclosure process.
This is in line with a previous reporting that ALHIV who were
not disclosed of their HIV-serostatus increased virological failure
by 5-fold (53). Unfortunately, we were unable to document
the adverse incidents after HIV disclosure. Transient negative
psychological effects and prolonged negative reactions that have
required the health care workers and parents’ support have been
described in the literature (54, 55).
Our study met several limitations. First, we enrolled less than
half of the APHIV who visited the sites during the inclusion
period due to logistical issues, which were mainly related to
health care workers overwork, with little time to enroll APHIV in
the study and get formal parental consent. Although we reported
no differences in the age, sex, and baseline immune status
between those included and excluded, there was a significant
difference in the participation rates between both sites (Lomé and
Abidjan), with APHIV from Lomé more likely to be enrolled.
In addition, the small sample size and relatively short follow-
up period have limited the statistical power of our analysis.
This flaw could have overshadowed an association between the
24-month health outcomes in APHIV and several variables
such as age, sex, and other relevant variables. Second, the
APHIV selected in our study were from urban teaching hospitals
specialized in adolescent HIV care where APHIV are likely to
receive a better standard of care compared to rural centers.
This affects the representativeness of our results to all ALHIV
in these countries but provides useful insights on the HIV care
practices at a country level. Third, the study design and few
time points during the follow-up period did not allow us to
perform a longitudinal analysis. Fourth, our data are relatively
old. Although the WHO guidelines have evolved recommending
new drugs, including dolutegravir since 2019 as the preferred
HIV treatment option in all populations, these drugs are not
yet available in Côte d’Ivoire and Togo in 2020. Thus, we feel
that despite the age of the data, our results reflect the current
situation in West Africa, and advocate for more potent drugs. In
addition, the COHADO cohort reported a small proportion of
adolescents lost to follow-up, reflecting a high quality of follow-
up in the selected sites. Our study provides the original data
documenting the feasibility and, indirectly, the positive effect of
accompanying actively the HIV disclosure process using health
care worker training on this topic and routine monitoring of this
crucial event.
Our results underscore important findings toward improving
the care of APHIV in West Africa. Since 2016, WHO
recommends HIV RNA viral load as the best indicator to evaluate
the ART response and viral load is universally recommended,
particularly for ALHIV who have a high risk of virological failure
(53, 56). However, this routine access to viral load remains
limited in the field level in West Africa. In a recent situation
analysis study, viral load monitoring was available in 43% of the
facilities across sub-Saharan Africa and only in 8% of the facilities
in West Africa (57). COHADO is one of the first West African
cohort studies to provide time trends in access to viral load in
West African adolescents. In the COHADO clinical sites, annual
viral load measurement is a recent opportunity that should be
scaled up, as virological success could also be an indicator used to
encourage treatment adherence and health outcomes of APHIV.
Conversely, identifying the virological failure early enough would
be helpful in reinforcing the treatment adherence more closely
to re-suppress viral load in this vulnerable population. Despite a
substantial increase in the access to viral load data from <30% at
inclusion to 84% at 24 months, we highlighted that still 16% have
their routine viral load data missing.
Furthermore, access to new ARV drugs, often left behind
in West Africa, remains crucial. As integrase inhibitors are
already being rolled out in other regions of the world since
2017, West Africa still struggles to access protease inhibitors,
and children and adolescents remain on NNRTI-based regimens
despite the sub-optimal PMTCT exposure and consequential
expected drug resistance emergence. In the COHADO cohort,
77.5% of APHIV were still receiving NNRTI-based regimens,
while 55% were failing on these regimens. In addition, although
we are not able to precisely document the frequency of HIV-
2 co-infection in our study, we also remind that West Africa
is endemic for HIV-2, described as having a natural resistance
to NNRTIs (58, 59). Our results advocate for a prompt roll-
out of more potent antiretroviral drugs accessible to West-
African APHIV. This also implies improving access to HIV
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genotyping to better identify the most appropriate regimens in
adolescents that have been exposed to several antiretroviral drugs
regimens, despite the limited laboratory capacity and high test
costs (60, 61).
CONCLUSION
Our study assessed the HIV-disclosure process and the 24-
month outcomes of APHIV in two West African urban clinical
sites. Although the frequency of full HIV disclosure remains
insufficient, this project has encouraged full HIV disclosure
practices, and the effect of HIV disclosure on the 24-month
outcome differed across sites, reflecting different standards of
care. This study contributes to a better understanding of the
disclosure process among APHIV. The disclosure of the APHIV
status is a crucial step in APHIV care and the disclosure process
should be initiated early, and not only for those at an advanced
stage of the disease. HIV disclosure should be addressed as a
dynamic process involving health care workers, counselors, and
parents or legal guardian as key players. Urgent interventions
are needed to support timely APHIV disclosure practices in both
caregivers and health care workers. These interventions should
be monitored over time and include caregivers and healthcare
providers and counselors.
Overall, the findings of the COHADO study also highlight the
insufficient response to the current treatment strategies. The 24-
month outcome of APHIV was favorable for less than half of
them. It is crucial to monitor the virological outcomes of ALHIV
on lifelong ART closely. There is an urgent need to improve
the treatment adherence, access to viral load monitoring, and
access to a more potent ART in West African cities. Our
results should guide HIV programs to optimize ALHIV quality
of care.
Finally, our study provides a reference to a tailored context-
specific intervention in West Africa. Cohort studies among
ALHIV such as in pWADA offer unique opportunities to
optimize monitoring, standardize data collection, and offer
interventional packages of care to integrate all specific ALHIV
issues including HIV disclosure, ART adherence, virological
outcomes, drug resistance, but also mental and sexual health
issues with the perspective of improving the 90-90-90 cascade of
care targets in the ALHIV population.
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